News

AMX0035 Extended Patients’ Survival By More Than 10 Months

Treatment with AMX0035 significantly extended the median survival of amyotrophic lateral sclerosis (ALS) patients by more than 10 months compared with a placebo, a new analysis of the Phase 2/3 CENTAUR clinical trial indicates. That survival difference was even greater in patients who continued to receive AMX0035 in the open-label…

Wave Life’s WVE-004 Shows Proof of Concept in Cell, Mouse Models

WVE-004, Wave Life Sciences‘ experimental therapy for people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72 gene, has demonstrated proof-of-concept efficacy in cell and animal models, a new study shows. The nucleic acid-based therapy was able to “potently” reduce the toxic RNA molecules and small proteins…